Alpha Beta T-cell and B-cell depleted allogeneic transplantation followed by Blinatumomab therapy for high-risk B-Acute Lymphoblastic Leukemia pilot study

Children’s Wisconsin is currently enrolling on this pilot study. This trial will assess the feasibility of alpha/beta T-cell and B-cell depleted allogeneic hematopoietic cell transplantation (HCT) followed by Blinatumomab therapy for high-risk B cell Acute Lymphoblastic Leukemia (ALL) as a means of reducing rates of subsequent relapse and improving survival, while also minimizing treatment-related morbidity/ mortality and late effects. The conditioning regimens will be dependent on the patient's minimal residual disease (MRD) status prior to HCT using high throughput sequencing. This multi-institutional study will be limited to 25 (estimated 10-15 per stratum) evaluable children, adolescents and young adults with B-ALL, that have experienced a relapse or have high-risk disease. Patients must be enrolled on our phase 2 Blinatumomab bridging study in order to be eligible for this study. identifier (NCT number): NCT04746209

Investigator and Study Chair: Rachel Phelan, MD, MPH

For more information contact: Tara Murphy | Clinical Research RN | 414-266-6471

Contact us

For more information about cancer and blood disorders clinical trials, email us or call

(414) 955-4727

Get a second opinion

It's important to know what your options are. We can provide expert opinions to verify or give more information about an initial diagnosis. Contact us today.

Why participate in clinical trials?

Michael Burke, MD

"The steady improvement in survival for children with cancer is a direct result of their enrollment onto clinical trials; without which we would remain decades behind in terms of scientific advances in pediatric cancer." ~Michael J. Burke, MD